EO-14357
Modifying Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China
- Signed
- Nov 4, 2025
- Published
- Nov 7, 2025
Federal Register: 2025-19825
Source: Federal Register.
Reduces China tariff tied to fentanyl supply chain from 20% to 10%
What it does
This order reduces an existing additional tariff on all goods imported from China from 20% to 10%, effective November 10, 2025. The reduction is granted in exchange for China's commitment to take steps to stop the flow of fentanyl and related chemical precursors to the United States and North America. The Department of Homeland Security is directed to monitor whether China follows through on its commitments, and the president reserves the right to raise tariffs again if China does not.
Who benefits
U.S. importers and retailers who purchase Chinese-made goods and would face lower input costs. Consumers who may see reduced prices on goods with Chinese-manufactured components. Small businesses that rely on Chinese imports for inventory or production materials. U.S. trading partners in North America (Canada, Mexico) that would benefit from China restricting chemical shipments to the region. Chinese exporters who regain partial market access to the U.S.
Who is affected
U.S. domestic manufacturers who compete with Chinese imports and benefited from the higher 20% tariff as a competitive buffer. Workers in industries that had gained a pricing advantage under the higher tariff. Families and communities affected by fentanyl addiction who may be skeptical that China's commitments will be honored. Law enforcement and public health agencies that had viewed the higher tariff as leverage. Federal revenue, which would decrease as the tariff rate is cut in half.
Supporters argue
Supporters argue that the tariff reduction is a measured diplomatic achievement: China has made concrete, verifiable commitments to restrict fentanyl precursor chemicals, and reducing the tariff rewards that cooperation while preserving the ability to reimpose higher duties if China fails to follow through. They contend that IEEPA grants the president broad authority to adjust economic measures in response to changing conditions during a declared national emergency, and that diplomatic engagement — backed by economic pressure — is the most effective tool available to reduce the supply of synthetic opioids entering the United States.
Opponents argue
Opponents argue that reducing the tariff before China has demonstrated sustained, verifiable action surrenders meaningful economic leverage prematurely, and that China's past commitments on fentanyl have not produced lasting results. They contend that cutting the tariff in half provides immediate, concrete relief to Chinese exporters while the promised benefits — reduced fentanyl flows — remain unproven and difficult to measure. Some also argue that using IEEPA tariffs as a diplomatic bargaining chip stretches the statute beyond its intended purpose of responding to genuine national security emergencies.
Constitutional basis
Executive orders rest on constitutional authority or statutory delegation. This summary describes the legal grounding cited or implied by the order.
The order invokes the International Emergency Economic Powers Act (IEEPA), 50 U.S.C. §1701 et seq., as the primary statutory authority, relying on the national emergency declared in EO 14195. It also cites the National Emergencies Act (50 U.S.C. §1601 et seq.), section 604 of the Trade Act of 1974 (19 U.S.C. §2483), and the president's general delegation authority under 3 U.S.C. §301, all of which function as statutory delegations of Article II foreign-affairs and commerce powers.